Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)

Talha Munir, Leyla Mohseninejad, Sheng Xu, Keri Yang, Rhys Williams, Remus Vezan, Nicolas Martinez-Calle

Blood (2025) 146 (Supplement 1): 7436.

https://doi.org/10.1182/blood-2025-7436

Published: 2025

Journal Articles

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States

Alvaro Alencar, Mei Xue, Qianhong Fu, Dong Yuan, Swetha Challagulla, Keri Yang

Blood (2025) 146 (Supplement 1): 8020.

https://doi.org/10.1182/blood-2025-8020

Published: 2025

Journal Articles

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Toby Eyre, Leyla Mohseninejad, Lianne Barnieh, Kaijun Wang, Keri Yang, Rhys Williams

Blood (2025) 146 (Supplement 1): 5365.

https://doi.org/10.1182/blood-2025-5365

Published: 2025

Journal Articles

Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan

Hirohiko Shibayama, Junji Suzumiya, Kuniharu Matsuno, Kazuki Kiyose, Mei Xue, Yan Meng, Todor I. Totev, Zhuo Chen, Keri Yang, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2025-4406

Published: 2025

Journal Articles

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Talha Munir, Paolo Sportoletti, Andrea Visentin, Leyla Mohseninejad, Lianne Barnieh, Keri Yang, Wassim Aldairy, Sheila Mpima, Vicky Casey, Rhys Williams, Raul Diez Fernandez, Francisco Javier Diaz Galvez, Vincent Levy

Blood (2025) 146 (Supplement 1): 8033.

https://doi.org/10.1182/blood-2025-8033

Published: 2025

Journal Articles

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies

Talha Munir, Paolo Sportoletti, Leyla Mohseninejad, Lianne Barnieh, Tushar Srivastava, Kate Ren, Wassim Aldairy, Ayad Ali, Keri Yang, Rhys Williams, Joe-Elie Salem

Blood (2025) 146 (Supplement 1): 8024.

https://doi.org/10.1182/blood-2025-8024

Published: 2025

Journal Articles

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Jennifer Brown, Swetha Challagulla, David Campbell, Qianhong Fu, Wassim Aldairy, Keri Yang, Rhys Williams, Constantine Tam

Blood (2025) 146 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2025-7443

Published: 2025

Journal Articles

Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment

Byung Woo Yoon, Suhyeon Lee, Mei Xue, Yan Meng, Dominic Pilon, Fengyi Jiang, Keri Yang, Sikander Ailawadhi

Blood (2025) 146 (Supplement 1): 7923.

https://doi.org/10.1182/blood-2025-7923

Published: 2025

Journal Articles

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States

Javier Pinilla-Ibarz, Swetha Challagulla, Qianhong Fu, Pengfei Cheng, Mei Xue, Keri Yang

Blood (2025) 146 (Supplement 1): 2762.

https://doi.org/10.1182/blood-2025-2762

Published: 2025

Journal Articles

Patients with high-risk features in Mantle Cell Lymphoma: A systematic literature review of clinical trials and real-world studies

Christine Ryan, Swetha Challagulla, Wesley Furnback, Mei Xue, Keri Yang, Alvaro Alencar

Blood (2025) 146 (Supplement 1): 8103.

https://doi.org/10.1182/blood-2025-8103

Published: 2025

Journal Articles

Number needed to treat to avoid progression or death: Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed/Refractory chronic lymphocytic leukemia

Mazyar Shadman, Jennifer Brown, David Campbell, Mei Xue, Marjan Massoudi, Rhys Williams, Keri Yang, Constantine Tam

Blood (2025) 146 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2025-4553

Published: 2025

Journal Articles

Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)

Sameh Gaballa, Mei Xue, Todor I Totev, Yan Meng, Swetha Challagulla, Zhuo Chen, Keri Yang

Blood (2024) 144 (Supplement 1): 3655.

https://doi.org/10.1182/blood-2024-204187

Published: 2024

Journal Articles

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

David Andorsky, Brittani Wayne, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A. Maglinte, Ira Zackon

Blood (2024) 144 (Supplement 1): 7763.

https://doi.org/10.1182/blood-2024-205940

Published: 2024

Journal Articles

Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)

Sikander Ailawadhi, Swetha Challagulla, Dominic Pilon, Yan Meng, Mei Xue, Yuxi Wang, Keri Yang

Blood (2024) 144 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2024-202786

Published: 2024

Journal Articles

Real-World Patterns of Care and Financial Burden of Patients with Follicular Lymphoma in the United States

Bijal D. Shah, Mei Xue, Erlene Kuizon Seymour, Wesley Furnback, Po-Ya Chuang, Keri Yang

Blood (2023) 142 (Supplement 1): 5137.

https://doi.org/10.1182/blood-2023-179556

Published: 2023

Journal Articles

Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Mazyar Shadman, Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Swetha Challagulla, Mei Xue, Rhys Williams, Susan M. O'Brien, Jennifer R. Brown, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2023-179222

Published: 2023

Journal Articles

Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Asher Alban Chanan-Khan, Swetha Challagulla, Elizabeth Donckels, Po-Ya Chuang, Keri Yang

Blood (2023) 142 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2023-179948

Published: 2023

Journal Articles

Real-World Switching Pattern, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Bijal D. Shah, Mei Xue, Wesley Furnback, Kaitlyn Esselman, Po-Ya Chuang, Keri Yang

Blood (2023) 142 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2023-178787

Published: 2023

Journal Articles

Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Talha Munir, Leyla Mohseninejad, Sheng Xu, Milica Jevdjevic, Walter Bouwmeester, Keri Yang

Blood (2023) 142 (Supplement 1): 6522.

https://doi.org/10.1182/blood-2023-173172

Published: 2023

Journal Articles

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Asher Alban Chanan-Khan, Kirollos S. Hanna, Mei Xue, Marjan Massoudi, Mark Balk, Hossein ZivariPiran, Cecilia Duan, Keri Yang

Blood (2023) 142 (Supplement 1): 2337.

https://doi.org/10.1182/blood-2023-174709

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States

Patients with high-risk features in Mantle Cell Lymphoma: A systematic literature review of clinical trials and real-world studies

Number needed to treat to avoid progression or death: Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed/Refractory chronic lymphocytic leukemia

Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)

Real-World Patterns of Care and Financial Burden of Patients with Follicular Lymphoma in the United States

Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Real-World Evaluation of Treatment Discontinuation and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Real-World Switching Pattern, Persistence, and Associated Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

Number Needed to Treat Analyses of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only